Seeking Alpha

Mario1

Mario1
Send Message
View as an RSS Feed
View Mario1's Comments BY TICKER:
Latest  |  Highest rated
  • Seadrill Limited's (SDRL) CEO Per Wullf on Q1 2015 Results - Earnings Call Transcript [View article]
    Back down to $10 over the next 3-4 months?
    May 28, 2015. 10:07 PM | Likes Like |Link to Comment
  • NeoStem prices equity offering; dilution depresses shares [View news story]
    This stock(like most stocks) are whores. They need to be treated like whores. Never buy and hold. Get in and get out quickly.
    May 28, 2015. 10:00 PM | 1 Like Like |Link to Comment
  • Zulily pummeled by downgrades after downcast earnings [View news story]
    How ridiculous that an analyst can change his price target from $45 to $18 and still gets to keep his job.
    Feb 16, 2015. 11:51 AM | 1 Like Like |Link to Comment
  • Update: Millennial Media Acquires Nexage [View article]
    thanks
    Jan 17, 2015. 09:55 AM | Likes Like |Link to Comment
  • Despite April 2014's Issue Of 'Journal Of The American College Of Cardiology,' NeoStem's AMR-001 Maintains Its Leverage For Stem Cell Based MI Treatment [View article]
    Shawn,
    I take it from your commentary that this news does not change anything for current and prospective investors in NBS. It is still the leader in the heart cell regenerative therapy category and is still poised to double or even triple over the next 6-8 months. Please respond if my interpretation of your article for NBS investors is correct. Thanks!
    Apr 6, 2014. 10:24 AM | 2 Likes Like |Link to Comment
  • 2 Cell Therapy Companies That Could Thrive With Cardiovascular Disease Treatments [View article]
    Brian does not makes mistakes.
    Feb 28, 2014. 07:25 PM | Likes Like |Link to Comment
  • 2 Cell Therapy Companies That Could Thrive With Cardiovascular Disease Treatments [View article]
    Another excellent article Brian.
    Feb 24, 2014. 10:00 AM | 2 Likes Like |Link to Comment
  • Could PCT Be NeoStem's Breakout Star? [View article]
    Excellent article Brian. The momentum continues to build for this stock. Hold and wait for the pops to come!!!
    Jan 27, 2014. 12:21 PM | 2 Likes Like |Link to Comment
  • Clearing Up Misconceptions About NeoStem's AMR-001 [View article]
    Adam,
    Where do you get that patients do not derive any clinically meaningful improvements in survivability????? Wake up and stop misleading people. CLearly, you have no idea how NBS works............

    #1 Known Data is Solid!

    AMR-001 is a cell therapy product comprised of autologous bone-marrow-derived CD34+/CXCR4+ cells. These cells are then used by NeoStem to treat and repair damaged heart muscles following a heart attack.

    CD34+ cells are often called the "workhorse of regeneration", as the regenerative abilities of these cells are often unquestioned. However, NeoStem's chief problem with AMR-001 had been finding a threshold dose, or a number of cells where the product was most effective.

    Last year, NeoStem found this threshold dose at 10 million cells, and when administered not one single patient had a deterioration in heart muscle function. This compared to a control group where doses of zero and five million cells were given, and in these patient populations approximately 30% to 40% saw a deterioration. Thus, the difference between zero to five and 10 million cells is without question significant, and it is this reason that investors should feel confident in NeoStem's opportunity with AMR-001.
    Jan 22, 2014. 06:07 PM | 5 Likes Like |Link to Comment
  • Best Buy's Dip Is A Great Opportunity [View article]
    Agreed Joe.
    Jan 22, 2014. 01:46 PM | 1 Like Like |Link to Comment
  • Best Buy's Dip Is A Great Opportunity [View article]
    Very good point.
    Jan 22, 2014. 01:46 PM | Likes Like |Link to Comment
  • Clearing Up Misconceptions About NeoStem's AMR-001 [View article]
    Excellent article SCIFI. TOOSMART is definitely not too smart here. Clearly he is short or wants to get cheaper shares but there is no reason PHASE II will not succeed. No other stem cell outfit has the top scientific minds, management, etc. that NBS has. Plus all the other business segments that NBS is in create a well diversified biotech IMO. We will see $16-25/share by end of 2014.
    Jan 22, 2014. 01:36 PM | 10 Likes Like |Link to Comment
  • Is 'Apples To Oranges' Really The Best Biotechnology Investment Strategy? [View article]
    Agreed. Brian is one of the top investment minds when it comes to the biotech space(top three IMO).
    Dec 10, 2013. 05:04 PM | Likes Like |Link to Comment
  • Is 'Apples To Oranges' Really The Best Biotechnology Investment Strategy? [View article]
    Craig,
    It would be NBS.
    Dec 2, 2013. 08:14 PM | Likes Like |Link to Comment
  • NeoStem: Major Developments You Might Have Missed [View article]
    Embryonic stem cells will never pass the political test. Does not matter how much better they are than adult stem cells. Stay out of embryonic arena unless you want to lose all your money down the road.
    Oct 30, 2013. 11:14 AM | Likes Like |Link to Comment
COMMENTS STATS
66 Comments
51 Likes